

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Bernd RIEDL et al. :
Serial No.: TO BE ASSIGNED : Group Art Unit: TO BE ASSIGNED
Filed: February 7, 2001 : Examiner: TO BE ASSIGNED
For: INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR
PYRIDYL UREAS



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

SIR:

Pursuant to 37 CFR §1.97 and §1.98, Applicant requests consideration in the above identified application the documents listed on the attached Form PTO-1449. Copies of the documents are in parent application serial number 09/452,228, filed October 22, 1999. The Examiner is requested to make these documents of record.

Applicants also identifies the following related copending applications.

	<u>Serial Number</u>	<u>Filing Date</u>	<u>Title</u>
Bayer 1	08/863,021	May 23, 1997	RAF Kinase Inhibitors
Bayer 2	08/863,022	May 23, 1997	RAF Kinase Inhibitors
Bayer 6 P1	Unassigned	December 22, 1998	Inhibition of RAF Kinase Using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas
Bayer 8 P1	09/479,125	December 22, 1998	Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas (Abandoned in favor of BAYER 8C1 Serial No. 09/640,780 filed August 18, 2000)
Bayer 9 C1	09/472,232	December 27, 1998	Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas

Bayer 10 C1	09/458,015	December 10, 1999	Inhibition of P38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas
Bayer 11 C1	09/458,014	December 10, 1999	Inhibition of P38 Kinase Activity Using Substituted Heterocyclic Ureas
Bayer 12 P1	Unassigned	December 22, 1998	Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
Bayer 16 P1	09/425,229	October 22, 1999	ω -Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors

The published International applications corresponding to the above application are as follows:


Bayer 1	WO 98/52559
Bayer 2	WO 98/52558
Bayer 6	WO 99/32436
Bayer 8	WO 99/32106
Bayer 9	WO 99/32455
Bayer 10	WO 99/32463
Bayer 11	WO 99/32111
Bayer 12	WO 99/32110
Bayer 16	WO 95/33458

This Information Disclosure Statement is being submitted within three months of the application filing date or before receipt of a first Office Action on the merits; no fee or separate requirements are required.

The Commissioner is hereby authorized to charge any fees which may be required by this statement to Deposit Account No. 13-3402.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Direct Dial: 703-812-5310
E-mail address: traverso@mwzb.com

Filed: February 7, 2001
RJT/lvb
K:\PAT\Bayer\15P3\ids 2-7-01.wpd